A new pharmacological role for donepezil: attenuation of morphine-induced tolerance and apoptosis in rat central nervous system.

BACKGROUND: Tolerance to the analgesic effect of opioids is a pharmacological phenomenon that occurs after their prolonged administration. It has been shown that morphine-induced tolerance is associated with apoptosis in the central nervous system and neuroprotective agents which prevented apoptosis signaling could attenuate tolerance to the analgesic effects. On the other hand donepezil, an acetylcholinesterase inhibitor, has been reported to have neuroprotective effects. Therefore in this study, the effect of systemic administration of donepezil on morphine-induced tolerance and apoptosis in the rat cerebral cortex and lumbar spinal cord was evaluated. Various groups of rats received morphine (ip) and different doses of donepezil (0, 0.5, 1, 1.5 mg/kg/day). Nociception was assessed using tail flick apparatus. Tail flick latency was recorded when the rat shook its tail. For apoptosis assay other groups of rats received the above treatment and apoptosis was evaluated by in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method. RESULTS: The results showed that administration of donepezil (0.5, 1, 1.5 mg/kg, ip) delayed the morphine tolerance for 9, 12 and 17 days, respectively. Furthermore pretreatment injection of donepezil attenuated the number of apoptotic cells in the cerebral cortex and lumbar spinal cord compared to the control group. CONCLUSION: In conclusion, we found that systemic administration of donepezil attenuated morphine-induced tolerance and apoptosis in the rat cerebral cortex and lumbar spinal cord.

Diagnostic value of serum adenosine deaminase activity in HIV infected patients of Kurdish population.

BACKGROUND: Adenosine deaminase (ADA) is a hydrolytic enzyme involved in the deamination of adenosine to inosine. ADA is involved in T-lymphocyte differentiation and development. This study was aimed to determine the diagnostic value of the adenosine deaminase (ADA) activity test for the diagnosis of HIV positive patients in the Kurdish population. METHODS: This descriptive analytical case-control study was performed on 30 healthy and 60 HIV positive subjects. Blood CD4+ cell count was recorded and serum total ADA, and ADA1 and ADA2 isoenzyme activities were determined. RESULTS: Serum total ADA and ADA2 isoenzyme activity was significantly higher in HIV positive patients than in healthy subjects. CD4+ cell counts markedly decreased in all patients and showed a significant inverse correlation with ADA activities. Using a cut-off level of 36.52 U/L and 30.98 U/L for serum total ADA and ADA2, respectively, sensitivity and specificity were 90.9% and 90.27% for total ADA and 93% and 90% for ADA2, respectively. CONCLUSIONS: Serum ADA was significantly increased in HIV infected patients. Therefore, because of its low cost and simplicity to perform, ADA activity might be considered a useful diagnostic tool among the other markers in this disease.